THTrine Allerslev Horsbøl

Trine Allerslev Horsbøl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Trine Allerslev Horsbøl has a total of 206 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cancer incidence among people with intellectual disability: a nationwide population-based cohort study in Denmark

    by Trine Toft Sørensen, Lau Caspar Thygesen, Susan Ishøy Michelsen, Knud Juel, Niels Lyhne Christensen, Susanne Oksbjerg Dalton, Ismail Gögenur, Mogens Groenvold, Lena Saltbæk, Trine Allerslev Horsbøl

  • Open Access

    Cancer Diagnostics Among People With Intellectual Disability—A Systematic Review

    by Rikke Harmsen, Josephine Marie Dyhr Olsen, Lau Caspar Thygesen, Trine Toft Sørensen, Liv Sund Troest, Susan Ishøy Michelsen, Knud Juel, Trine Allerslev Horsbøl

    Background: People with intellectual disability (ID) have a markedly lower life expectancy than the general population, with cancer being one of the most common causes of death. This systematic review aims to provide an overview of existing knowledge on cancer diagnostics among people with ID, including cancer screening, routes to cancer diagnosis and cancer stage. Method: We systematically searched Embase, PubMed, CINAHL and PsycInfo for observational studies on cancer screening, routes to diagnosis, and cancer stage among people with ID published from 2000 onwards. Study selection and quality assessment were conducted independently by two authors. Results: Twenty‐five register‐based studies met the inclusion criteria. Sixteen consistently reported lower cancer screening participation among people with ID. Three studies found that people with ID were less likely to be diagnosed through standardized, fast‐track pathways and more likely to be diagnosed following emergency hospital contacts. Across nine studies, people with ID were more often diagnosed at advanced or unknown cancer stage than those without ID. Conclusions: People with ID experience substantial inequalities in cancer detection, including lower screening participation, less optimal diagnostic pathways and more frequent diagnosis at advanced or unknown stages. These disparities highlight the need for interventions targeting symptom recognition, diagnostic pathways and healthcare accessibility among people with ID.

  • Frailty and quality of life in a real‐world multiple myeloma population

    by Klara F. K. Rydahl, Sören Möller, Trine Allerslev Horsbøl, Birgit Bjerre Høyer, Bo Amdi Jensen, Carsten Helleberg, Anja Klostergaard, Henrik Gregersen, Sarah Farmer, Mikael Frederiksen, et al.

    Summary: Frailty is common in multiple myeloma (MM) and is associated with inferior outcomes. Knowledge on quality of life (QoL) primarily originates from clinical trials, where frail patients are often not included. In this nationwide, longitudinal observational study, QoL was assessed in 681 Danish patients with newly diagnosed MM (NDMM) or relapsed or refractory MM (RRMM) with symptomatic disease using patient‐reported outcomes collected over 2 years of follow‐up between 2017 and 2021. Patients were categorized as fit, intermediate‐fit or frail according to the International Myeloma Working Group (IMWG) frailty score. Preselected QoL domains from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ‐C30), the Chemotherapy‐Induced Peripheral Neuropathy module (EORTC QLQ‐CIPN20) and the Short‐form health survey (SF12) questionnaires were analysed using linear mixed models and interpreted in terms of clinical relevance. At inclusion, frail patients reported clinically relevant lower global QoL and physical functioning, and more fatigue compared to fit patients. Frail NDMM patients reported improvement in global QoL and pain during follow‐up, whereas physical functioning and fatigue remained unchanged. Frail RRMM patients reported unchanged global QoL and fatigue, and deterioration in physical functioning and more pain during follow‐up. Our results based on a real‐world population show that QoL findings from clinical trial populations cannot directly be applied to frail patients.

  • Elevated Risks for Depression and Anxiety Following Diagnosis of Multiple Myeloma

    by Klara F. K. Rydahl, Andreas Kiesbye Øvlisen, Trine Allerslev Horsbøl, Sören Möller, Lene Kongsgaard Nielsen, Søren Dinesen Østergaard, Tarec Christoffer El‐Galaly, Christopher Rohde

    Background: Patients with multiple myeloma (MM) may be particularly vulnerable to depression and anxiety following diagnosis due to high disease burden, treatment‐related side effects, and the incurable nature of the disease. Methods: In this nationwide population‐based cohort study, we used Danish population‐based registries to investigate the risk of depression and anxiety in patients with MM (symptomatic MM and smoldering MM) compared with age‐ and sex‐matched individuals from the general population. Results: A total of 3861 patients with MM and 19 305 matched comparators were included (median age 73 years; 59% male). During follow‐up, depression and/or anxiety occurred in 315 MM patients (8.2%) and 660 comparators (3.4%). MM was associated with a substantially increased risk of depression and/or anxiety (adjusted HR 2.56, 95% CI 2.23–2.94). The association was strongest among patients with symptomatic MM (adjusted HR 2.63, 95% CI 2.21–3.12) but remained elevated among patients with smoldering MM (adjusted HR 1.44, 95% CI 1.10–1.87). The association was strongest during the first year following diagnosis and attenuated over time. Conclusion: These findings demonstrate an elevated risk of depression and/or anxiety among patients with both symptomatic and smoldering MM and highlight the need for increased awareness of psychological morbidity, particularly during the first year after diagnosis.

  • Open Access

    Colorectal Cancer Screening Among People With Intellectual Disabilities

    by Trine Allerslev Horsbøl, Susan Ishøy Michelsen, Trine Toft Sørensen, Knud Juel, Morten Rasmussen, Ismail Gögenur, Susanne Oksbjerg Dalton, Amina Banda, Maarten Cuypers, Lau Caspar Thygesen

    Importance: Colorectal cancer mortality is elevated among people with intellectual disabilities, potentially because of delayed diagnosis. Objective: To compare colorectal cancer screening participation and completion among people with and without intellectual disabilities. Design, Setting, and Participants: This nationwide, register-based cohort study was conducted in Denmark, where all residents aged 50 to 74 years are invited to biennial, free-of-charge colorectal cancer screening. People with and without intellectual disabilities born between 1940 and 1973 and invited to colorectal cancer screening at least once between 2014 and 2023 were included. Exposure: Intellectual disability, defined as being registered with an intellectual disability diagnosis or a diagnosis most likely leading to intellectual disability. Disability severity (mild, moderate, severe, and profound) was available for a subpopulation. Main Outcomes and Measures: The primary outcomes were colorectal cancer screening participation and completion, including stool sample return, screening results, and diagnostic examination (mainly colonoscopy) following a positive screening test result. The pseudo-observations method was used to estimate cumulative incidence differences and cumulative incidence ratios between people with and without intellectual disability. Results: The study included 17 117 people with (median [IQR] age, 55.2 [50.2 to 63.2] years; 8445 female [49.3%]) and 149 162 without (median [IQR] age, 54.8 [50.2 to 62.5] years; 75 324 female [50.5%]) intellectual disabilities. Among those, 5170 people with intellectual disabilities (30.2%) and 83 709 people without (56.1%) returned a stool sample within 90 days of first invitation (adjusted cumulative incidence difference, −23.2 percentage points; 95% CI, −24.0 to −22.4 percentage points), with participation increasing with disability severity (range, 1453 of 5293 individuals with mild [27.5%] to 198 of 488 individuals with profound [40.6%] intellectual disabilities). Nonanalyzable samples were more common among people with vs without intellectual disabilities (105 individuals [1.8%] vs 330 individuals [0.4%]). Among those with a positive screening test result, 347 people (70.5%) with intellectual disabilities and 4724 (90.2%) without underwent diagnostic examination (mainly colonoscopy) within 60 days (adjusted cumulative incidence difference, −17.9 percentage points; 95% CI, −22.1 to −13.7 percentage points). The proportion who underwent diagnostic examination decreased with increasing disability severity (range, 127 of 165 individuals with mild [77.0%] to 50 of 100 individuals with moderate to profound [50.0%] intellectual disabilities). Colonoscopies were more often incomplete among people with vs those without intellectual disabilities (109 individuals [28.2%] vs 673 individuals [13.8%]). Conclusions and Relevance: In this cohort study of people with and without intellectual disabilities, those with intellectual disabilities were less likely to participate in colorectal cancer screening and, when they did participate, more often encountered challenges with stool sample collection and colonoscopy completion. These disparities call for tailored, decision-supportive strategies to ensure equitable access to colorectal cancer screening.


  • Advancing equity for people with intellectual disabilities: Closing the neglected cancer policy gap

    by Martin McMahon, Suzanne Denieffe, Kate Sykes, Peter Knapp, Maarten Cuypers, Pınar Soylar, Adela Elena Popa, Dalia Ismail Ibrahim, Bahar Aksoy, Seda Cansu Yeniğün Akbulut, et al.


  • Open Access

    Work ability following breast cancer – the MyHealth randomized controlled trial

    by Trine A. Horsbøl, Lena Saltbæk, Caroline Urhammer, Randi V. Karlsen, Christoffer Johansen, Pernille E. Bidstrup, Beverley L. Høeg, Vibeke Zoffmann, Federica Belmonte, Ingelise Andersen, et al.

    Background and purpose: We previously demonstrated positive effects on quality of life and mental health following breast cancer when comparing a nurse-led follow-up program without scheduled visits (MyHealth) to regular follow-up. This study aims to examine whether MyHealth also positively impacts self-reported work ability. Patients/material and methods: A total of 288 patients, potentially active on the labour market, were randomized to MyHealth or control follow-up after primary treatment for early-stage breast cancer (2017–2019). MyHealth included individual self-management sessions, electronic symptom monitoring, and assistance with navigating healthcare services. Control follow-up consisted of biannual outpatient visits with a physician. Linear mixed-effect models were applied to evaluate the effect of MyHealth on self-reported work ability at 6, 12, 24, and 36 months after randomization as measured by the Work Ability Score (WAS). Results: Work ability increased significantly in both groups during the first 6 months (mean WAS increase MyHealth: 1.64, 95% confidence interval [CI]: 1.26; 2.02 and control: 1.57, 95% CI: 1.17; 1.97) and continued to increase slightly but non-significantly (p-values > 0.13) until end of follow-up at 36 months. Improvement was especially pronounced among patients reporting poor work ability at baseline. Differences in mean WAS between patients in MyHealth and control follow-up were non-significant and close to zero at all time points (–0.21 to 0.48). Interpretation: The MyHealth follow-up program had no additional effect on self-reported work ability compared to regular follow-up. Future interventions should target patients with poor work ability and include components specifically designed to enhance work ability.


  • Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial

    by Lena Saltbæk, Pernille E. Bidstrup, Randi V. Karlsen, Beverley L. Høeg, Trine A. Horsboel, Federica Belmonte, Elisabeth A.W. Andersen, Vibeke Zoffmann, Anne S. Friberg, Mads N. Svendsen, et al.

    PURPOSE: Follow-up after breast cancer with regular visits has failed to detect recurrences, be cost-effective, and address patient needs. METHODS: MyHealth is a phase III randomized controlled trial (ClinicalTrials.gov identifier: NCT02949167 ). Patients, who recently completed primary treatment for stage I-II breast cancer, were randomly assigned in variable block sizes and stratified by age and human epidermal growth factor receptor 2 status to intervention or control follow-up. The nurse-led intervention comprised three to five individual self-management sessions, regular reporting of symptoms, and navigation to health care services. The control follow-up comprised regular outpatient visits with the physician. The primary outcome was breast cancer–specific quality of life (QoL) measured by the Trial Outcome Index-Physical/Functional/Breast summary score of the Functional Assessment of Cancer Therapy-Breast 2 years after random assignment. Secondary outcomes were fear of recurrence, anxiety, depression, and health care utilization. Analyses were intention-to-treat and P values were two-sided with 95% confidence level set at 0.005 because of multiple comparisons. RESULTS: Among 1,101 eligible patients, 875 were invited and 503 were randomly assigned to control (n = 252) or intervention (n = 251) follow-up. At 2 years, patients in the intervention group reported a significantly and clinically relevant higher QoL (mean, 75.69 [standard deviation [SD], 12.27]) than patients in the control group (71.26 [SD, 14.08]), with a mean difference of 5.05 (95% CI, 3.30 to 6.79; P < .001). The intervention group reported significantly less fear of recurrence, anxiety, and depression; they had fewer physician consultations but more nurse contacts and an unchanged diagnostic imaging pattern. The effect on all outcomes was stable through a 3-year follow-up. CONCLUSION: The MyHealth study suggested a new strategy for follow-up after early breast cancer as it provided significant improvements in QoL.


  • Open Access

    Loneliness and the risk of type 2 diabetes

    by Siri Rosenkilde, Sofie Have Hoffmann, Anne Bonde Thorsted, Trine Allerslev Horsbøl, Katrine Rich Madsen, Sara Fokdal Lehn, Allan Kofoed-Enevoldsen, Peter Bindslev Iversen, Marie Stjerne Grønkjær, Lau Caspar Thygesen

    Introduction The incidence of type 2 diabetes is increasing globally. Recent research suggests that loneliness could be a potential risk factor for the development of type 2 diabetes. We aimed to investigate the association between loneliness and type 2 diabetes and the modifying effect of mental disorders. Research design and methods We conducted a prospective study including 465 290 adults (aged ≥16 years) who participated in either the Danish Health and Morbidity Survey or the Danish National Health Survey between 2000 and 2017. Loneliness was based on self-report, while type 2 diabetes was measured using an algorithm combining several health registers including type 2 diabetes patients treated both within the hospital sector and general practice. Cox proportional hazards regressions were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs). Results During a mean follow-up time of 6.3 years, 13 771 individuals (3%) developed type 2 diabetes. Feeling lonely once in a while was associated with a 14% increased risk of type 2 diabetes (95% CI 1.09 to 1.20), while feeling lonely often was associated with a 24% increased risk (95% CI 1.14 to 1.34), independent of sociodemographic factors and body mass index. The association was stronger among individuals without a mental disorder (HR 1.21, 95% CI 1.10 to 1.34 among those feeling lonely often) compared with those with a mental disorder (HR 1.07, 95% CI 0.93 to 1.23). Conclusions Loneliness independently increased the risk of type 2 diabetes. The effect was more pronounced in individuals without a mental disorder, as having a mental disorder itself likely increases the risk of type 2 diabetes. These findings emphasize the importance of addressing loneliness as a modifiable risk factor in preventing type 2 diabetes.


  • Educational outcomes and the role of comorbidity among adolescents with type 1‐diabetes in Denmark

    by Anne Bonde Thorsted, Lau Caspar Thygesen, Sofie Have Hoffmann, Siri Rosenkilde, Sara Fokdal Lehn, Louise Lundby‐Christensen, Trine Allerslev Horsbøl

    Aims: To examine educational outcomes among adolescents with type 1 diabetes and determine the role of comorbidity.Methods: We conducted a nationwide register‐based cohort study including 3370 individuals born between 1991 and 2003 and diagnosed with type 1 diabetes before the age of 16. They were all matched with up to four individuals without type 1 diabetes on age, gender, parents' educational level and immigration status. Information on comorbidity was based on hospital diagnoses. The individuals were followed in registers to determine whether they finished compulsory school (9th grade, usually at the age of 15–16 years), and were enrolled in secondary education by age 18 years.Results: Individuals with type 1 diabetes were more likely not to complete compulsory school (OR 1.44, 95% CI 1.26–1.64), and not being enrolled in an upper secondary education by age 18 (OR 1.50, 95% CI 1.31–1.73) compared to their peers. A total of 1869 (56%) individuals with type 1 diabetes were registered with at least one somatic (n = 1709) or psychiatric comorbidity (n = 389). Those with type 1 diabetes and psychiatric comorbidity were more likely not to complete compulsory school (OR 2.47, 95% CI 1.54–3.96), and not being enrolled in an upper secondary education by age 18 (OR 3.66, 95% CI 2.27–5.91) compared to those with type 1 diabetes only. Further, there was a tendency towards an association between having somatic comorbidity and adverse educational outcomes (OR 1.25, 95% CI 0.97–1.63; OR 1.26, 95% CI 0.95–1.66) among adolescents with type 1 diabetes. The associations differed markedly between diagnostic comorbidity groups.Conclusion: Type 1 diabetes affects educational attainment and participation among adolescents. Psychiatric comorbidity contributes to adverse educational outcomes in this group, and there is a tendency that somatic comorbidity also plays a role.